Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety

NCT01912391 is registered in ClinicalTrials.gov with Mood and Anxiety Research, Inc as lead sponsor.

NCT NCT01912391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01912391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized Double-blind, 12 Week, Placebo Controlled Trial of Transdermal Selegiline in Borderline Personality Disorder (BPD) to Evaluate Efficacy and Safety
Lead sponsor
Mood and Anxiety Research, Inc
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2012
Completion date
March 31, 2015
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

borderline personality disorder